Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 599-malignant-breast-disorders-without-cc-mcc
    Ask Trek AI about this page

    Malignant Breast Disorders without CC/MCC: Inpatient Reimbursement Overview

    DRG 599 encompasses inpatient stays for malignant breast disorders without a Complication or Comorbidity or Major Complication or Comorbidity, typically involving surgical treatment or brief diagnostic admissions. This grouping matters for inpatient reimbursement because it standardizes payment for cases with similar clinical complexity and resource needs under Medicare rules.

    Customize your policy alerts

    Sign up for drg 599 policy alerts

    Get alerted when payer policies referencing 599 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 599 Overview

    DRG 599 covers inpatient admissions for malignant breast disorders without a Complication or Comorbidity and without a Major Complication or Comorbidity. Typical cases include primary malignant neoplasms of the breast managed with surgical procedures or short inpatient stays for diagnostic or therapeutic interventions. This Diagnosis-Related Group matters for Medicare payment because it groups clinically similar cases with comparable resource use, determining base reimbursement for hospitals under the inpatient prospective payment system. Understanding the clinical scope helps hospitals anticipate payment levels for straightforward malignant breast disease admissions.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative de-escalation and surgical technique trials: studies comparing less extensive axillary surgery (sentinel lymph node biopsy alone) versus traditional axillary lymph node dissection in patients with early-stage malignant breast disease without major comorbidities. These trials enroll patients admitted for definitive breast surgery and seek to define operative approaches that maintain oncologic control while reducing length of stay, complication rates (lymphedema, seroma), and readmissions. Evidence from this research informs inpatient coding, resource utilization, and episode cost for hospitals and payers by identifying procedures that safely shorten hospitalization and downstream care needs.
    • Neoadjuvant pathologic response and tailoring of adjuvant therapy trials: prospective studies evaluating biomarkers and imaging to predict pathologic complete response after neoadjuvant systemic therapy in operable breast cancer, with the aim of personalizing subsequent surgical extent or adjuvant treatment. These studies focus on patients who present for inpatient or short-stay surgical management after preoperative systemic therapy, tracking how response-guided decisions affect reoperation rates, inpatient complications, and post-discharge therapy utilization. Results are relevant to providers and payers because they influence inpatient case mix, timing of surgery, and allocation of inpatient resources for patients who may avoid more extensive procedures or require additional perioperative care.
    • Post-discharge recovery, rehabilitation, and quality-of-care outcomes studies: observational cohorts and pragmatic trials assessing postoperative recovery pathways (enhanced recovery protocols, outpatient drain management, physical therapy timing) and patient-reported outcomes in patients treated for malignant breast disease without major complications. These studies enroll the typical DRG 599 population—patients without CC/MCC undergoing breast-conserving surgery or mastectomy—and measure readmission, wound-related returns, functional outcomes, and utilization of home health or outpatient services. Findings guide hospitals and payers on interventions that reduce readmissions and post-acute costs while improving functional recovery and patient satisfaction for this lower-complexity inpatient group.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.